Literature DB >> 16377126

Gold-induced reactive oxygen species (ROS) do not mediate suppression of monocytic mitochondrial or secretory function.

Yo Omata1, Jill B Lewis, Petra E Lockwood, Wan Y Tseng, Regina L Messer, Serge Bouillaguet, John C Wataha.   

Abstract

UNLABELLED: The toxicity of anti-rheumatic gold compounds has limited their use and development, yet both the toxicological and therapeutic actions of these compounds remain unclear. In the current study, we tested the hypothesis that intracellular reactive oxygen species (ROS) induced by Au(I) or Au(III) compounds mediate their ability to suppress mitochondrial activity.
METHODS: Human THP1 monocytes were exposed to HAuCl(4) x 3H(2)O (Au(III)), or the anti-rheumatic compounds auranofin (AF) or gold sodium thiomalate (GSTM) for 6-72 h, after which mitochondrial activity (succinate dehydrogenase) was measured. To assess the role of cellular redox status as a mediator of mitochondrial suppression, monocytes were pre-treated with a pro-oxidant (t-butyl hydroquinone, t-BHQ) or antioxidant (N-acetyl cysteine, NAC ). ROS levels were measured 0-24h post-gold addition to determine their role as mediators of mitochondrial activity suppression.
RESULTS: AF was the most potent inhibitor of mitochondrial activity, followed by Au(III) and GSTM. Only Au(III) induced intracellular ROS; no ROS formation was observed in response to AF or GSTM exposure. Although anti- and pro-oxidants had some effects on mitochondrial suppression of Au compounds, collectively the data do not support redox effects or ROS formation as major mediators of Au-compound mitochondrial suppression.
CONCLUSIONS: Our results do not indicate that ROS and redox effects play major roles in mediating the cytotoxicity of AF, GSTM or Au(III).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16377126     DOI: 10.1016/j.tiv.2005.11.001

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  3 in total

Review 1.  The biological activity of auranofin: implications for novel treatment of diseases.

Authors:  J M Madeira; D L Gibson; W F Kean; A Klegeris
Journal:  Inflammopharmacology       Date:  2012-09-11       Impact factor: 4.473

2.  Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth.

Authors:  Ningning Liu; Xiaofen Li; Hongbiao Huang; Chong Zhao; Siyan Liao; Changshan Yang; Shouting Liu; Wenbin Song; Xiaoyu Lu; Xiaoying Lan; Xin Chen; Songgang Yi; Li Xu; Lili Jiang; Canguo Zhao; Xiaoxian Dong; Ping Zhou; Shujue Li; Shunqing Wang; Xianping Shi; Ping Q Dou; Xuejun Wang; Jinbao Liu
Journal:  Oncotarget       Date:  2014-07-30

3.  Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms.

Authors:  Xin Chen; Xianping Shi; Chong Zhao; Xiaofen Li; Xiaoying Lan; Shouting Liu; Hongbiao Huang; Ningning Liu; Siyan Liao; Dan Zang; Wenbin Song; Quentin Liu; Bing Z Carter; Q Ping Dou; Xuejun Wang; Jinbao Liu
Journal:  Oncotarget       Date:  2014-10-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.